|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arslan C and Yalcin S: Current and future
systemic treatment options in metastatic pancreatic cancer. J
Gastrointest Oncol. 5:280–295. 2014.PubMed/NCBI
|
|
4
|
Chen J, Xiao-Zhong G and Qi XS: Clinical
outcomes of specific immunotherapy in advanced pancreatic cancer: A
systematic review and meta-analysis. J Immunol Res.
2017:82823912017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lopez de Lapuente A, Alloza I, Goertsches
R, Zettl UK, Urcelay E, Arroyo R, Comabella M, Montalban X,
Antigüedad A and Vandenbroeck K: Analysis of the IL28RA locus as
genetic risk factor for multiple sclerosis. J Neuroimmunol.
245:98–101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sheppard P, Kindsvogel W, Xu W, Henderson
K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C,
Roraback J, et al: IL-28, IL-29 and their class II cytokine
receptor IL-28R. Nat Immunol. 4:63–68. 2003. View Article : Google Scholar
|
|
7
|
Syedbasha M, Linnik J, Santer D, O'Shea D,
Barakat K, Joyce M, Khanna N, Tyrrell DL, Houghton M and Egli A: An
ELISA based binding and competition method to rapidly determine
ligand-receptor interactions. J Vis Exp. 109:535752016.
|
|
8
|
Wack A, Terczyńska-Dyla E and Hartmann R:
Guarding the frontiers: The biology of type III interferons. Nat
Immunol. 16:802–809. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maher SG, Sheikh F, Scarzello AJ,
Romero-Weaver AL, Baker DP, Donnelly RP and Gamero AM: IFNalpha and
IFNlambda differ in their antiproliferative effects and duration of
JAK/STAT signaling activity. Cancer Biol Ther. 7:1109–1115. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heidari Z, Moudi B, Mahmoudzadeh-Sagheb H
and Hashemi M: The correlation between interferon lambda 3 gene
polymorphisms and susceptibility to hepatitis B virus infection.
Hepat Mon. 16:e342662016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wei H, Wang S, Chen Q, Chen Y, Chi X,
Zhang L, Huang S, Gao GF and Chen JL: Suppression of interferon
lambda signaling by SOCS-1 results in their excessive production
during influenza virus infection. PLoS Pathog. 10:e10038452014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lazear HM, Daniels BP, Pinto AK, Huang AC,
Vick SC, Doyle SE, Gale M Jr, Klein RS and Diamond MS: Interferon-λ
restricts west nile virus neuroinvasion by tightening the
blood-brain barrier. Sci Transl Med. 7:pp. 284ra592015, View Article : Google Scholar
|
|
13
|
Syedbasha M and Egli A: Interferon lambda:
Modulating immunity in infectious diseases. Front Immunol.
8:1192017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zitzmann K, Brand S, Baehs S, Göke B,
Meinecke J, Spöttl G, Meyer H and Auernhammer CJ: Novel
interferon-lambdas induce antiproliferative effects in
neuroendocrine tumor cells. Biochem Biophys Res Commun.
344:1334–1341. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meager A, Visvalingam K, Dilger P, Bryan D
and Wadhwa M: Biological activity of interleukins-28 and -29:
Comparison with type I interferons. Cytokine. 31:109–118. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dumoutier L, Tounsi A, Michiels T,
Sommereyns C, Kotenko SV and Renauld JC: Role of the interleukin
(IL)-28 receptor tyrosine residues for antiviral and
antiproliferative activity of IL-29/interferon-lambda 1:
Similarities with type I interferon signaling. J Biol Chem.
279:32269–32274. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kotenko SV, Gallagher G, Baurin VV,
Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H
and Donnelly RP: IFN-lambdas mediate antiviral protection through a
distinct class II cytokine receptor complex. Nat Immunol. 4:69–77.
2003. View Article : Google Scholar
|
|
18
|
Yang L, Wei WC, Meng XN, Gao J, Guo N, Wu
FT and Zeng WW: Significance of IL28RA in diagnosis of early
pancreatic cancer and its regulation to pancreatic cancer cells by
JAK/STAT signaling pathway-effects of IL28RA on pancreatic cancer.
Eur Rev Med Pharmacol Sci. 23:9863–9870. 2019.PubMed/NCBI
|
|
19
|
Vitale G, van Eijck CH, van KoetsveldIng
PM, Erdmann JI, Speel EJ, van der WansemIng K, Mooij DM, Colao A,
Lombardi G, Croze E, et al: Type I interferons in the treatment of
pancreatic cancer: Mechanisms of action and role of related
receptors. Ann Surg. 246:259–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mucha J, Majchrzak K, Taciak B, Hellmén E
and Król M: MDSCs mediate angiogenesis and predispose canine
mammary tumor cells for metastasis via IL-28/IL-28RA (IFN-λ)
signaling. PLoS One. 9:e1032492014. View Article : Google Scholar
|
|
21
|
Hui XW, Chen H, Zhang S, Ma X, Wang X and
Huang B: Antitumor activities of recombinant human interferon
(IFN)-λ1 in vitro and in xenograft models in vivo for colon cancer.
Cancer Lett. 311:141–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pancreatic Surgery Group of Surgery Branch
of Chin: Guideline for the diagnosis and treatment of pancreatic
adenocarcinoma (2014 edition). Chin J Digest Surg. 11:831–837.
2014.
|
|
23
|
Ding Y, He J, Huang J, Yu T, Shi X, Zhang
T, Yan G, Chen S and Peng C: Harmine induces anticancer activity in
breast cancer cells via targeting TAZ. Int J Oncol. 54:1995–2004.
2019.PubMed/NCBI
|
|
24
|
Shansky RM: Are hormones a 'female
problem' for animal research? Science. 364:825–826. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
http://sydwzx.ahmu.edu.cn/2017/0114/c6570a79605/page.htm.
|
|
26
|
Bloomston M, Shafii A, Zervos EE and
Rosemurgy AS: TIMP-1 overexpression in pancreatic cancer attenuates
tumor growth, decreases implantation and metastasis, and inhibits
angiogenesis. J Surg Res. 102:39–44. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Glassman DC, Palmaira RL, Covington CM,
Desai AM, Ku GY, Li J, Harding JJ, Varghese AM, O'Reilly EM and Yu
KH: Nanoliposomal irinotecan with fluorouracil for the treatment of
advanced pancreatic cancer, a single institution experience. BMC
Cancer. 18:6932018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang F, Jin R, Zou BB, Li L, Cheng FW, Luo
X, Geng X and Zhang SQ: Activation of Toll-like receptor 7
regulates the expression of IFN-λ1, p53, PTEN, VEGF, TIMP-1 and
MMP-9 in pancreatic cancer cells. Mol Med Rep. 13:1807–1812. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang L, Wei J and He S: Integrative
genomic analyses on interferon-lambdas and their roles in cancer
prediction. Int J Mol Med. 25:299–304. 2010.PubMed/NCBI
|
|
30
|
Lasfar A, Gogas H, Zloza A, Kaufman HL and
Kirkwood JM: IFN-λ cancer immunotherapy: New kid on the block.
Immunotherapy. 8:877–888. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sato A, Ohtsuki M, Hata M, Kobayashi E and
Murakami T: Antitumor activity of IFN-lambda in murine tumor
models. J Immunol. 176:7686–7694. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bromberg JF, Horvath CM, Wen Z, Schreiber
RD and Darnell JE Jr: Transcriptionally active Stat1 is required
for the antiproliferative effects of both interferon alpha and
interferon gamma. Proc Natl Acad Sci USA. 93:7673–7678. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Quintás-Cardama A and Verstovsek S:
Molecular pathways: Jak/STAT pathway: Mutations, inhibitors, and
resistance. Clin Cancer Res. 19:1933–1940. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ramana CV, Grammatikakis N, Chernov M,
Nguyen H, Goh KC, Williams BR and Stark GR: Regulation of c-myc
expression by IFN-gamma through Stat1-dependent and -independent
pathways. EMBO J. 19:263–272. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang S, Bucana CD, Van Arsdall M and
Fidler IJ: Stat1 negatively regulates angiogenesis, tumorigenicity
and metastasis of tumor cells. Oncogene. 21:2504–2512. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kaplan DH, Shankaran V, Dighe AS, Stockert
E, Aguet M, Old LJ and Schreiber RD: Demonstration of an interferon
gamma-dependent tumor surveillance system in immunocompetent mice.
Proc Natl Acad Sci USA. 95:7556–7561. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baer R, Cintas C, Therville N and
Guillermet-Guibert J: Implication of PI3K/Akt pathway in pancreatic
cancer: When PI3K isoforms matter? Adv Biol Regul. 59:19–35. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ebrahimi S, Hosseini M, Shahidsales S,
Maftouh M, Ferns GA, Ghayour-Mobarhan M, Hassanian SM and Avan A:
Targeting the Akt/PI3K signaling pathway as a potential therapeutic
strategy for the treatment of pancreatic cancer. Curr Med Chem.
24:1321–1331. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu CY, Carpenter ES, Takeuchi KK, Halbrook
CJ, Peverley LV, Bien H, Hall JC, DelGiorno KE, Pal D, Song Y, et
al: PI3K regulation of RAC1 is required for KRAS-induced pancreatic
tumorigenesis in mice. Gastroenterology. 147:1405–1416.e7. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Reichert M, Saur D, Hamacher R, Schmid RM
and Schneider G: Phosphoinositide-3-kinase signaling controls
S-phase kinase-associated protein 2 transcription via E2F1 in
pancreatic ductal adenocarcinoma cells. Cancer Res. 67:4149–4156.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guenterberg KD, Grignol VP, Raig ET,
Zimmerer JM, Chan AN, Blaskovits FM, Young GS, Nuovo GJ, Mundy BL,
Lesinski GB and Carson WE III: Interleukin-29 binds to melanoma
cells inducing Jak-STAT signal transduction and apoptosis. Mol
Cancer Ther. 9:510–520. 2010. View Article : Google Scholar : PubMed/NCBI
|
